Serotonergic and dopaminergic systems in anorexia nervosa: a role for atypical antipsychotics?

References

• Beumont P JV, Ben-Tovim D, Touyz S. Eating Disorders. Foundations of clinical psychiatry2nd edn., S Bloch, B S Singh. Melbourne University Press, Melbourne 2001; 217–230
   Google Scholar
• Harris E C, Barraclough B. Excess mortality of mental disorder. British Journal of Psychiatry 1998; 173: 11–53
   PubMed Web of Science ®Google Scholar
• Theander S. Outcome and prognosis in anorexia nervosa and bulimia: some results of previous investigations compared with those of a Swedish long term study. Journal of Psychiatric Research 1985; 19: 493–508
   PubMed Web of Science ®Google Scholar
• Sullivan P F. Mortality in anorexia nervosa. American Journal of Psychiatry 1995; 152: 1073–1074
   PubMed Web of Science ®Google Scholar
• Herzog D B, Nussbaum K M, Marmor A K. Comorbidity and outcome in eating disorders. Psychiatric Clinics of North America 1996; 19: 843–859
   PubMed Web of Science ®Google Scholar
• Herzog D B, Keller M B, Lavori P W. Outcome in anorexia nervosa and bulimia: a review of the literature. Journal of Nervous and Mental Disease 1988; 176: 131–143
   PubMed Web of Science ®Google Scholar
• Garfinkel P E, Walsh B T. Drug Therapies. Handbook of treatment for eating disorders, D M Garner, P E Garfinkel. Guilford, New York 1997; 372–382
   Google Scholar
• Walters E E, Kendler K S. Anorexia and anorexic-like syndromes in a population-based female twin sample. American Journal of Psychiatry 1995; 152: 64–71
   PubMed Web of Science ®Google Scholar
• Touyz S W, Kopec-Schrader E M, Beumont P JV. Anorexia nervosa in males. a report of 12 cases. Australian and New Zealand Journal of Psychiatry 1993; 27: 512–517
   PubMed Web of Science ®Google Scholar
• Andersen A E. Males with eating disorders. Bruner/ Mazel, New York 1990
   Google Scholar
• Lask B, Bryant-Waugh R. Childhood onset of anorexia nervosa and related eating disorders. Erlbaum, Hove, UK 1993
   Google Scholar
• Cosford P, Arnold E. Eating disorders in later life. International Journal of Geriatric Psychiatry 1992; 7: 491–498
   Web of Science ®Google Scholar
• Devaud C, Michaud P A, Narring F. Anorexia and bulimia: increasing disorders? A review of the literature on the epidemiology of eating disorders. Revue D Epidemiologie et de Sante Publique 1995; 43: 347–360
   PubMedGoogle Scholar
• Eagles J M, Johnston M I, Hunter D, Lobban M, Millar H R. Increasing incidence of anorexia nervosa in the female population of northeast Scotland. American Journal of Psychiatry 1995; 152: 1266–1271
   PubMed Web of Science ®Google Scholar
• Jarman M, Walsh S. Evaluating recovery from anorexia nervosa and bulimia nervosa: integrating lessons learned from research and clinical practice. Clinical Psychology Review 1999; 19: 773–788
   PubMed Web of Science ®Google Scholar
• Ward A, Campbell I C, Brown N, Treasure J. Anorexia nervosa subtypes: differences in recovery. Journal of Nervous and Mental Disease 2003; 191: 197–201
   PubMed Web of Science ®Google Scholar
• Windauer U, Lennerts W, Talbot P, Touyz S W, Beumont P J. How well are ‘cured’ anorexia nervosa patients? An investigation of 16 weight-recovered anorexic patients. The British Journal of Psychiatry 1993; 163: 195–200
   PubMed Web of Science ®Google Scholar
• Pike K M. Long-term course of anorexia nervosa: response, relapse, remission, and recovery. Clinical Psychology Review 1998; 18: 447–475
   PubMed Web of Science ®Google Scholar
• Royal Australian and New Zealand College of Psychiatrists Clinical Practice Guideline Team for Anorexia Nervosa. Australian and New Zealand clinical practice guidelines for the treatment of anorexia nervosa. Australian and New Zealand Journal of Psychiatry 2004; 38: 659–670
   PubMed Web of Science ®Google Scholar
• Yager J, Andersen A, Devlin M, et al. Practice guideline for the treatment of patients with eating disorders. Practice guidelines for the treatment of psychiatric disorders compendium 20022nd edn. American Psychiatric Press, Washington DC 2002; 697–766
   Google Scholar
• Gilchrist P, Ben-Tovim D, Hay P H, Kalucy R, Walker M K. Eating disorders revisited. I: anorexia nervosa. Medical Journal of Australia 1998; 169: 438–441
   PubMed Web of Science ®Google Scholar
• Becker A E, Grinspoon S K, Kiblanski A, Herzog D B. Eating disorders. New England Journal of Medicine 1999; 340: 1092–1098
   PubMed Web of Science ®Google Scholar
• Taylor D M, McAskill R. Atypical antipsychotics and weight gain-a systematic review. Acta Psychiatrica Scandinavica 2000; 101: 416–432
   PubMed Web of Science ®Google Scholar
• Dally P, Sargant W. A new treatment of anorexia nervosa. British Medical Journal 1960; 1: 1770–1773
   PubMed Web of Science ®Google Scholar
• Dally P, Sargant W. Treatment and outcome of anorexia nervosa. British Medical Journal 1966; 2: 793–795
   PubMed Web of Science ®Google Scholar
• Vandereycken W, Pierloot R. Pimozide combined with behaviour therapy in the short-term treatment of anorexia nervosa: a double-blind placebo-controlled cross-over study. Acta Psychiatrica Scandinavica 1982; 66: 445–450
   PubMed Web of Science ®Google Scholar
• Vandereycken W. Neuroleptics in the short-term treatment of anorexia nervosa. A double-blind placebo-controlled study with sulpiride. British Journal of Psychiatry 1984; 144: 288–292
   PubMed Web of Science ®Google Scholar
• Cassano G B, Miniati M, Pini S, et al. Six-month open trial of haloperidol as an adjunctive treatment for anorexia nervosa: a preliminary report. International Journal of Eating Disorders 2003; 33: 172–177
   PubMed Web of Science ®Google Scholar
• Thiel A. Is psychopharmacotherapy necessary in Anorexia and Bulimia Nervosa?. Psychotherapie, Psychosomatik Medizinische Psychologie 1997; 47: 332–345
   PubMed Web of Science ®Google Scholar
• Fichter M M. Medication for anorexia and bulimia nervosa: a review. Der Nervenarzt 1993; 64: 21–35
   PubMed Web of Science ®Google Scholar
• Mitchell J E, de Zwaan M, Roerig J L. Drug therapy for patients with eating disorders. Current Drug Targets-CNS and Neurological Disorders 2003; 2: 17–29
   PubMedGoogle Scholar
• Strober M. Locus of control, psychopathology, and weight gain in juvenile anorexia nervosa. Journal of Abnormal Child Psychology 1982; 10: 97–106
   PubMed Web of Science ®Google Scholar
• Bruch H. Treatment in anorexia nervosa. International Journal of Psychoanalytic Psychotherapy 1982-1983; 9: 303–312
   PubMedGoogle Scholar
• Attia E, Haiman C, Walsh B T, Flater S R. Does fluoxetine augment the inpatient treatment of anorexia nervosa?. American Journal of Psychiatry 1998; 51: 548–551
   Web of Science ®Google Scholar
• Bergh C, Eriksson M, Lindberg G, Sodersten P. Selective serotonin reuptake inhibitors in anorexia. Lancet 1996; 348: 1459–1460
   PubMed Web of Science ®Google Scholar
• Gwirtsman H E, Guze B H, Yager J, Gainsley B. Fluoxetine treatment of anorexia nervosa: an open clinical trial. Journal of Clinical Psychiatry 1990; 51: 378–382
   PubMed Web of Science ®Google Scholar
• Kaye W, Gendall K, Strober M. Serotonin neuronal function and selective serotonin reuptake inhibitor treatment in anorexia and bulimia nervosa. Biological Psychiatry 1998; 44: 825–838
   PubMed Web of Science ®Google Scholar
• Kapur S, Remington G. Atypical antipsychotics: new directions and new challenges in the treatment of schizophrenia. Annual Review of Medicine 2001; 52: 503–517
   PubMed Web of Science ®Google Scholar
• Seeman P. Atypical antipsychotics: mechanism of action. Canadian Journal of Psychiatry 2002; 47: 27–38
   PubMed Web of Science ®Google Scholar
• Stahl S M. ‘Hit-and-run’ actions at dopamine receptors, part 1: mechanism of action of atypical antipsychotics. Journal of Clinical Psychiatry 2001; 62: 670–671
   PubMed Web of Science ®Google Scholar
• Ichikawa J, Ishii H, Bonaccorso S, Fowler W L, O'Laughlin I A, Meltzer H Y. 5-HT (2A) and D (2) receptor blockade increases cortical DA release via 5-HT (1A) receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release. Journal of Neurochemistry 2001; 76: 1521–1531
   PubMed Web of Science ®Google Scholar
• Barbarich N C, Kaye W H, Jimerson D. Neurotransmitter and imaging studies in anorexia nervosa: new targets for treatment. Current Drug Targets –CNS and Neurological Disorders 2003; 2: 61–72
   PubMedGoogle Scholar
• Binder E B, Kinkead B, Nemeroff C B. Neuropeptides. Current issues in the psychopharmacology of schizophrenia, A Breier, P V Tran, J M Herrera, G D Tollefson, F P Bymaster. Lippincott Williams & Wilkins, Philadelphia 2001; 349–371
   Google Scholar
• Kaye W, Strober M. The neurobiology of eating disorders. Neurobiology of mental illness, D S Charney, E J Nestler, B S Bunney. Oxford University Press, New York 1999; 891–906
   Google Scholar
• Crawley J N. Cholecystokinin-dopamine interactions. Trends in Pharmacological Sciences 1991; 12: 232–236
   PubMed Web of Science ®Google Scholar
• Baptista T, Beaulieu S. Are leptin and cytokines involved in body weight gain during treatment with antipsychotic drugs?. Canadian Journal of Psychiatry 2002; 47: 742–749
   PubMed Web of Science ®Google Scholar
• Herran A, Garcia-Unzueta M T, Amado J A, de La Maza M T, Alvarez C, Vazquez-Barquero J L. Effects of long-term treatment with antipsychotics on serum leptin levels. The British Journal of Psychiatry 2001; 179: 59–62
   PubMed Web of Science ®Google Scholar
• Kraus T, Haack M, Schuld A, et al. Body weight and leptin plasma levels during treatment with antipsychotic drugs. American Journal of Psychiatry 1999; 156: 312–314
   PubMed Web of Science ®Google Scholar
• Leibowitz S F. Differential functions of hypothalamic galanin cell grows in the regulation of eating and body weight. Annals of the New York Academy of Sciences 1998; 863: 206–220
   PubMed Web of Science ®Google Scholar
• Leibowitz S F, Shor-Posner G. Brain serotonin and eating behaviour. Appetite 1986; 7: 1–14
   PubMed Web of Science ®Google Scholar
• Blundell J E. Serotonin and appetite. Neuropharmacology 1984; 23: 1537–1551
   PubMed Web of Science ®Google Scholar
• Wurtman J J, Wurtman R J. Drugs that enhance central serotoninergic transmission diminish elective carbohydrate consumption by rats. Life Sciences 1979; 24: 895–903
   PubMed Web of Science ®Google Scholar
• Fernstrom J D, Wurtman R J. Brain serotonin content: increase following ingestion of carbohydrate diet. Science 1971; 174: 1023–1025
   PubMed Web of Science ®Google Scholar
• Fernstrom J D, Wurtman R J. Brain serotonin content: physiological regulation by plasma neutral amino acids. Science 1971; 178: 414–416
   Web of Science ®Google Scholar
• Kaye W H, Weltzin T E. Serotonin activity in anorexia and bulimia nervosa. relationship to the modulation of feeding and mood. Journal of Clinical Psychiatry 1991; 52(Suppl.)41–48
   PubMedGoogle Scholar
• Cowen P J, Clifford E M, Walsh A E, Williams C, Fairburn C G. Moderate dieting causes 5-HT2C receptor supersensitivity. Psychological Medicine 1996; 26: 1155–1159
   PubMed Web of Science ®Google Scholar
• Kaye W H, Barbarich N C, Putnam K, et al. Anxiolytic effects of acute tryptophan depletion in anorexia nervosa. International Journal of Eating Disorders 2003; 33: 257–267
   PubMed Web of Science ®Google Scholar
• Brewerton T D. Toward a unified theory of serotonin dysregulation in eating and related disorders. Psychoneuroendocrinology 1995; 20: 561–590
   PubMed Web of Science ®Google Scholar
• Bulik C M, Sullivan P F, Joyce P R, Carter F A. Temperament, character and personality disorder in bulimia nervosa. Journal of Nervous and Mental Disorders 1995; 183: 593–572
   PubMed Web of Science ®Google Scholar
• Deep A L, Nagy L M, Weltzin T E, Rao R, Kaye W H. Premorbid onset of psychopathology in long-term recovered anorexia nervosa. International Journal of Eating Disorders 1995; 17: 291–297
   PubMed Web of Science ®Google Scholar
• Kaye W H, Weltzin T E, Hsu L KG, Bulik C M, McConaha C, Sobkiewicz T. Patients with anorexia nervosa have elevated scores on the Yale-Brown Obsessive-Compulsive Scale. International Journal of Eating Disorders 1992; 12: 57–62
   Web of Science ®Google Scholar
• Kaye W H, Ebert M H, Raleigh M, Lake R. Abnormalities in CNS monoamine metabolism in anorexia nervosa. Archives of General Psychiatry 1984; 41: 350–355
   PubMed Web of Science ®Google Scholar
• Kaye W H, Gwirtsman H E, George D T, Jimerson D C, Ebert M H. CSF 5-HIAA concentrations in anorexia nervosa: reduced values in underweight subjects normalise after weight gain. Biological Psychiatry 1988; 23: 102–105
   PubMed Web of Science ®Google Scholar
• Kaye W H, Gwirtsman H E, George D T, Ebert M H. Altered serotonin activity in anorexia nervosa after long-term weight restoration: does elevated CSF 5-HIAA correlate with rigid and obsessive behaviour?. Archives of General Psychiatry 1991; 48: 556–562
   PubMed Web of Science ®Google Scholar
• Brewerton T D. Towards a united theory of serotonin dysregulation in eating and related disorders. Psychoneuroendocrinology 1995; 20: 561–590
   PubMed Web of Science ®Google Scholar
• Frank G K, Kaye W H, Weltzin T E, et al. Altered response to meta-chlorophenylpiperazine in anorexia nervosa: support for a persistent alteration of serotonin activity after short-term weight restoration. International Journal of Eating Disorders 2001; 30: 57–68
   PubMed Web of Science ®Google Scholar
• Brewerton T D, Jimerson D C. Studies of serotonin function in anorexia nervosa. Psychiatry Research 1996; 62: 31–42
   PubMed Web of Science ®Google Scholar
• Monteleone P, Brambilla F, Bortolotti F, La Rocca A, Maj M. Prolactin response to d-fenfluramine is blunted in people with anorexia nervosa. The British Journal of Psychiatry 1998; 172: 439–442
   PubMed Web of Science ®Google Scholar
• O'Dwyer A M, Lucey J V, Russell G F. Serotonin activity in anorexia nervosa after long-term weight restoration: response to D-fenfluramine challenge. Psychological Medicine 1996; 26: 353–359
   PubMed Web of Science ®Google Scholar
• Ward A, Brown N, Lightman S, Campbell I C, Treasure J. Neuroendocrine, appetitive and behavioural responses to d-fenfluramine in women recovered from anorexia nervosa. British Journal of Psychiatry 1998; 172: 351–358
   PubMed Web of Science ®Google Scholar
• Fink G, Sumner B EH. Oestrogen and mental state. Nature 1996; 383: 306
   PubMed Web of Science ®Google Scholar
• Garfinkel P E, Lin E, Goering P, et al. Should amenorrhoea be necessary for the diagnosis of anorexia nervosa? Evidence from a Canadian community sample. British Journal of Psychiatry 1996; 168: 500–506
   PubMed Web of Science ®Google Scholar
• Frank G K, Kaye W H, Meltzer C C, et al. Reduced 5-HT2A receptor binding after recovery from anorexia nervosa. Biological Psychiatry 2002; 52: 896–906
   PubMed Web of Science ®Google Scholar
• Volkow N D, Wang G J, Fowler J S, et al. ‘Nonhedonic’ food motivation in humans involves dopamine in the dorsal striatum and methylphenidate amplifies this effect. Synapse 2002; 44: 175–180
   PubMed Web of Science ®Google Scholar
• Volkow N D, Wang G J, Maynard L, et al. Brain dopamine is associated with eating behaviours in humans. International Journal of Eating Disorders 2003; 33: 36–142
   Web of Science ®Google Scholar
• Aou S. Physiology of appetite and feeding behaviour: introduction. Japanese Journal of Clinical Medicine 2001; 59: 407–412
   PubMedGoogle Scholar
• Kaye W H, Frank G K, McConaha C. Altered dopamine activity after recovery from restricting-type anorexia nervosa. Neuropsychopharmacology 1999; 21: 503–506
   PubMed Web of Science ®Google Scholar
• Barry V, Klavans H L. On the role of dopamine in the pathophysiology of Anorexia Nervosa. Journal of Neural Transmission 1976; 38: 107–122
   PubMed Web of Science ®Google Scholar
• Devesa J, Perez-Fernandez R, Bokser L, Gaudiero G J, Lima L, Casanueva F F. Adrenal androgen secretion and dopaminergic activity in anorexia nervosa. Hormone and Metabolic Research 1988; 20: 57–60
   PubMed Web of Science ®Google Scholar
• Golden N H, Pepper G M, Sacker I, Avruskin T W. The effects of a dopamine antagonist on luteinizing hormone and prolactin release in women with anorexia nervosa and in normal controls. Journal of Adolescent Health 1992; 13: 155–160
   PubMed Web of Science ®Google Scholar
• Brambilla F, Bellodi L, Arancio C, Ronchi P, Limonta D. Central dopaminergic function in anorexia and bulimia nervosa: a psychoneuroendocrine approach. Psychoneuroendocrinology 2001; 26: 393–409
   PubMed Web of Science ®Google Scholar
• Boachie A, Goldfield G S, Spettigue W. Olanzapine use as an adjunctive treatment for hospitalised children with anorexia nervosa: case reports. International Journal of Eating Disorders 2003; 33: 98–103
   PubMed Web of Science ®Google Scholar
• Bosanac P, Burrows G, Norman T. Olanzapine in anorexia nervosa. Australian and New Zealand Journal of Psychiatry 2003; 37: 494
   PubMed Web of Science ®Google Scholar
• Mehler C, Wewetzer C, Sculze U, Warnke A, Thiesen F, Dittmann R W. Olanzapine in children and adolescents with chronic anorexia nervosa: a study of five cases. European Child and Adolescent Psychiatry 2001; 10: 151–157
   PubMed Web of Science ®Google Scholar
• Ruiz-Lazaro P M, Pueyo A. Use of olanzapine for the treatment of anorexia nervosa in a male adolescent. Revista de Psiquiatria Infanto-Juvenil 2001; 3: 29–31
   Google Scholar
• Jensen V S, Mejlhede A. Anorexia nervosa: treatment with olanzapine. British Journal of Psychiatry 2000; 177: 87
   PubMed Web of Science ®Google Scholar
• La Via M, Gray N, Kaye W H. Case reports of olanzapine treatment of anorexia nervosa. International Journal of Eating Disorders 2000; 27: 363–366
   PubMed Web of Science ®Google Scholar
• Hansen L. Olanzapine in the treatment of anorexia nervosa. British Journal of Psychiatry 1999; 175: 592
   PubMed Web of Science ®Google Scholar
• Newman-Toker J. Risperidone in anorexia nervosa. Journal of the American Academy of Child and Adolescent Psychiatry 2000; 39: 941–942
   PubMed Web of Science ®Google Scholar
• Conte G, Canmardese G, Cesaro C. Before and during the treatment of two cases of severe anorexia nervosa: the use of an atypical antipsychotic drug. Psicoterapia e Istituzioni: Review of Psychoanalytical Methodological Research and Clinical Experiences 1999; 6: 187–190
   Google Scholar
• Fisman S, Steele M, Short J, Byrne T, Lavallee C. Case study: Anorexia nervosa and autistic disorder in an adolescent girl. Journal of the American Academy of Child and Adolescent Psychiatry 1996; 35: 937–940
   PubMed Web of Science ®Google Scholar
• Powers P S, Santana C A, Bannen Y S. Olanzapine in the treatment of anorexia nervosa: an open label trial. International Journal of Eating Disorders 2002; 32: 146–154
   PubMed Web of Science ®Google Scholar
• Kay S R, Fiszbein A, Opler L A. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophrenia Bulletin 1987; 13: 261–276
   PubMed Web of Science ®Google Scholar
• Hamilton M. A rating scale for depression. Journal of Neurology, Neurosurgery and Psychiatry 1960; 23: 56
   PubMed Web of Science ®Google Scholar
• Garner D M. Eating disorder inventory-2: professional manual. Psychological Assessment Resources, Odessa, FL 1991
   Google Scholar
• Malina A, Gaskill J, McConaha C, et al. Olanzapine treatment of anorexia nervosa: a retrospective study. International Journal of Eating Disorders 2003; 33: 234–237
   PubMed Web of Science ®Google Scholar
• Gaskill J, Treat T, McCabe E, Marcus M. Does olanzapine affect the rate of weight gain among inpatients with eating disorders?. Eating Disorders Review 2001; 12: 1–2
   Google Scholar
• Fairburn C G, Cooper Z. The eating disorders examination. Binge eating: nature, assessment and treatment12th edition, C G Fairburn, G T Wilson. Guilford, New York 1993; 317–360
   Google Scholar
• Sanavio E. Obsessions and compulsions: the Padua Inventory. Behaviour Research and Therapy 1988; 26: 169–177
   PubMed Web of Science ®Google Scholar
• Montecchi F, Magnani M, Marinucci S, Gambara M, Diamanti A. Risperidone in the control of negative symptoms in anorexia nervosa in adolescents. Minerva Psichiatrica 1998; 39: 205–209
   Google Scholar
• Derogatis L R, Cleary P A. Factorial invariance across gender for the primary symptom dimensions of the SCL-90. British Journal of Social and Clinical Psychology 1977; 16: 47–356
   PubMed Web of Science ®Google Scholar
• Bianco G, Claps M, Marinucci S, Montecchi F. Use of risperidone in adolescent anorexia nervosa. Italian Journal of Psychiatry and Behavioural Sciences 2000; 10: 50–52
   Google Scholar
• Ruggiero G M, Laini N, Mauri M C, et al. A single blind comparison of amisulpride, fluoxetine and clomipramine in the treatment of restricting anorectics. Progress in Neuro-Psychopharmacology and Biology Psychiatry 2001; 25: 1049–1059
   PubMed Web of Science ®Google Scholar
• Keller M B, Lavori P W, Friedman B, et al. The longitudinal interval follow-up evaluation. A method for assessing outcome in prospective longitudinal studies. Archives of General Psychiatry 1987; 44: 540–548
   PubMed Web of Science ®Google Scholar
• Geller J. Estimating readiness for change in anorexia nervosa: comparing clients, clinicians, and research assessors. International Journal of Eating Disorders 2002; 31: 251–260
   PubMed Web of Science ®Google Scholar
• Vitousek K, Watson S, Wilson G T. Enhancing motivation for change in treatment-resistant eating disorders. Clinical Psychology Review 1998; 18: 391–420
   PubMed Web of Science ®Google Scholar